Anavex Life Sciences Corp (AVXL)

[Talon38]

Bio, Good link. Dr. O'Niell reiterates what his colleagues Dr Sandrock and three other Drs described in the deleted Biogen Lab Video....the secret to successfully treating M/S lies in remyelination of the nerves that have been attacked by the body's immune system. 2-73 has proved to do this in the WSU preclinicals and highly probably in the ANAVEX/Biogen MTA in vivo study. Biogen's own remyelination candidate, Opicinumab, has struggled to do that in a recent P2 trial to repair optic nerve demyelination. The question is whether 2-73 is a better remyelinator or can it assist Opicinumab. Would be willing to bet those questions have or on their way to be answered by the MTA

IMHO, the current withholding of information lies in the answering of the above question and the subsequent discussion between Missling and Vournatsos on where we go from here.

One other question that is obvious is how these drugs turn off the overactive immune response.